Compare LAES & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAES | ATYR |
|---|---|---|
| Founded | 2022 | 2005 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 675.0M | 49.2M |
| IPO Year | 2022 | 2015 |
| Metric | LAES | ATYR |
|---|---|---|
| Price | $2.30 | $0.31 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 9 |
| Target Price | ★ $4.00 | $3.67 |
| AVG Volume (30 Days) | ★ 4.3M | 2.6M |
| Earning Date | 03-31-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.98 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $190,000.00 |
| Revenue This Year | $93.36 | N/A |
| Revenue Next Year | $43.06 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.99 | $0.28 |
| 52 Week High | $8.71 | $1.12 |
| Indicator | LAES | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 43.47 | 27.82 |
| Support Level | $2.22 | N/A |
| Resistance Level | $2.61 | $0.59 |
| Average True Range (ATR) | 0.09 | 0.03 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 35.19 | 16.37 |
SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America, while it also has its presence in Europe, Middle East & Africa, Asia Pacific, and Latin America.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).